NGHIÊN CỨU NỒNG ĐỘ INTERLEUKIN 6 VÀ MỘT SỐ YẾU TỐ LIÊN QUAN Ở BỆNH NHÂN VIÊM PHỔI CỘNG ĐỒNG ĐIỀU TRỊ NỘI TRÚ TẠI BỆNH VIỆN ĐA KHOA VĨNH LONG NĂM 2024-2025

Abstract

Backgruond: Community-acquired pneumonia (CAP) remains a prevalent respiratory disease with significant morbidity and mortality, despite advances in diagnosis and treatment. Objectives: To determine and compare IL-6 levels among subgroups of patients with communityacquired pneumonia patients treated at Vinh Long General Hospital in 2024-2025. Materials and methods: This cross-sectional descriptive study was conducted on a cohort of 120 inpatients diagnosed with community-acquired pneumonia at Vinh Long General Hospital over the period from July 2024 to February 2025. Data collection was carried out using a standardized protocol, and statistical analyses were performed using SPSS software, version 20.0 Results: The majority of patients were aged 60 years or older, accounting for 85.0% of the study population, with males comprising 62.5%. Disease severity assessment using the CURB-65 scoring system revealed that 87.5% of patients had mild disease, 10.0% moderate and 2.5% severe. The rate of favorable treatment outcomes was 82.5%. Serum IL-6 levels exceeding 7 pg/mL were observed in 72.5% of patients, with the highest recorded value being 640.2 pg/mL, the lowest 2.2 pg/mL, and a median of 17.1 pg/mL. Statistical analysis demonstrated a significant association between elevated IL-6 levels and the presence of fever as well as treatment outcomes (p<0.05). Conclusion: These findings suggest that IL-6 may serve as a potential biomarker for disease severity and prognosis in CAP. Further studies are warranted to elucidate the clinical utility of IL-6 in guiding therapeutic strategies for CAP.